UNSPSC 51283935: Sulfadicramide

This classification denotes a sulfonamide antiinfective with the molecular formula C11H14N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WZ5EG263C, chemically known as n'-(3,3-dimethylacroyl)sulfanilamide but generally known as sulfadicramide, which bears US NIH Compound Identifier 8281. The term SULFADICRAMIDE is an International Non-Proprietary Name or INN. European Medicines Agency schedules sulfadicramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10697MIG.

Most nations schedule sulfadicramide under HS 29350090 and SITC 51580. As of Q4 2014, SULFADICRAMIDE remains the US FDA Preferred Term for this commodity. SMILES: CC(=CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N)C.

UNSPSC 51283935 Sulfadicramide is a Commodity code that captures pharmaceutical products and related supplies procured by state and local health agencies, though recent opportunities tagged under this code show minimal direct activity for the named product itself. State and local health departments, county health systems, and community health authorities use codes in this pharmaceutical family to acquire specialized medications, antibiotic compounds, and emergency medical supplies through cooperative purchasing vehicles and competitive bidding. The Illinois Department of Public Health and Seminole County, Florida are recent issuing bodies in this space, though their posted opportunities reflect broader pharmaceutical and emergency-response procurement rather than sulfadicramide specifically—the Illinois opportunity involved antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through a piggyback contract with Chartwell Rx LLC, and the Seminole County solicitation sought Naloxone and drug deactivation systems for community health initiatives.

Activity under this Commodity code appears concentrated in Florida and Illinois based on recent postings, with the Illinois Department of Public Health executing a $2,999,999.11 three-year piggyback pharmaceutical contract through the MMCAP Infuse consortium awarded to Chartwell Rx LLC on August 28, 2026, and Seminole County, Florida posting an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year initial term. The disconnect between the code name and recent opportunities—sulfadicramide versus antibiotic tablets and emergency-response medications—suggests limited current market activity under this specific Commodity designation, warranting verification of relevant recent solicitations before committing pursuit resources.